These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Bupropion in the treatment of pathological gambling: a randomized, double-blind, placebo-controlled, flexible-dose study. Black DW; Arndt S; Coryell WH; Argo T; Forbush KT; Shaw MC; Perry P; Allen J J Clin Psychopharmacol; 2007 Apr; 27(2):143-50. PubMed ID: 17414236 [TBL] [Abstract][Full Text] [Related]
25. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. Wilens TE; Spencer TJ; Biederman J; Girard K; Doyle R; Prince J; Polisner D; Solhkhah R; Comeau S; Monuteaux MC; Parekh A Am J Psychiatry; 2001 Feb; 158(2):282-8. PubMed ID: 11156812 [TBL] [Abstract][Full Text] [Related]
26. Evaluation of rotigotine transdermal patch for the treatment of apathy and motor symptoms in Parkinson's disease. Hauser RA; Slawek J; Barone P; Dohin E; Surmann E; Asgharnejad M; Bauer L BMC Neurol; 2016 Jun; 16():90. PubMed ID: 27267880 [TBL] [Abstract][Full Text] [Related]
27. An open-label, rater-blinded, 8-week trial of bupropion hydrochloride extended-release in patients with major depressive disorder with atypical features. Seo HJ; Lee BC; Seok JH; Jeon HJ; Paik JW; Kim W; Kwak KP; Han C; Lee KU; Pae CU Pharmacopsychiatry; 2013 Sep; 46(6):221-6. PubMed ID: 23963965 [TBL] [Abstract][Full Text] [Related]
28. Neuropsychiatric symptoms are very common in premanifest and early stage Huntington's Disease. Martinez-Horta S; Perez-Perez J; van Duijn E; Fernandez-Bobadilla R; Carceller M; Pagonabarraga J; Pascual-Sedano B; Campolongo A; Ruiz-Idiago J; Sampedro F; Landwehrmeyer GB; ; Kulisevsky J Parkinsonism Relat Disord; 2016 Apr; 25():58-64. PubMed ID: 26898966 [TBL] [Abstract][Full Text] [Related]
29. Effect of Methylphenidate on Apathy in Patients With Alzheimer Disease: The ADMET 2 Randomized Clinical Trial. Mintzer J; Lanctôt KL; Scherer RW; Rosenberg PB; Herrmann N; van Dyck CH; Padala PR; Brawman-Mintzer O; Porsteinsson AP; Lerner AJ; Craft S; Levey AI; Burke W; Perin J; Shade D; JAMA Neurol; 2021 Nov; 78(11):1324-1332. PubMed ID: 34570180 [TBL] [Abstract][Full Text] [Related]
30. Assessing Mental Health Difficulties of Persons With Huntington's Disease: Does Informant Presence Make a Difference? Gunn S; Maltby J; Dale M J Neuropsychiatry Clin Neurosci; 2020; 32(3):244-251. PubMed ID: 32102601 [TBL] [Abstract][Full Text] [Related]
31. The Neuropsychiatry of Huntington Disease-Like 2: A Comparison with Huntington's Disease. Ferreira-Correia A; Krause A; Anderson DG J Huntingtons Dis; 2020; 9(4):325-334. PubMed ID: 33044188 [TBL] [Abstract][Full Text] [Related]
32. Bupropion and restless legs syndrome: a randomized controlled trial. Bayard M; Bailey B; Acharya D; Ambreen F; Duggal S; Kaur T; Rahman ZU; Roller K; Tudiver F J Am Board Fam Med; 2011; 24(4):422-8. PubMed ID: 21737767 [TBL] [Abstract][Full Text] [Related]
33. Rivastigmine in apathetic but dementia and depression-free patients with Parkinson's disease: a double-blind, placebo-controlled, randomised clinical trial. Devos D; Moreau C; Maltête D; Lefaucheur R; Kreisler A; Eusebio A; Defer G; Ouk T; Azulay JP; Krystkowiak P; Witjas T; Delliaux M; Destée A; Duhamel A; Bordet R; Defebvre L; Dujardin K J Neurol Neurosurg Psychiatry; 2014 Jun; 85(6):668-74. PubMed ID: 24218528 [TBL] [Abstract][Full Text] [Related]
34. A pilot study using nabilone for symptomatic treatment in Huntington's disease. Curtis A; Mitchell I; Patel S; Ives N; Rickards H Mov Disord; 2009 Nov; 24(15):2254-9. PubMed ID: 19845035 [TBL] [Abstract][Full Text] [Related]
35. Course of irritability, depression and apathy in Huntington's disease in relation to motor symptoms during a two-year follow-up period. van Duijn E; Reedeker N; Giltay EJ; Eindhoven D; Roos RA; van der Mast RC Neurodegener Dis; 2014; 13(1):9-16. PubMed ID: 23948661 [TBL] [Abstract][Full Text] [Related]
36. Apathy Profile in Parkinson's and Huntington's Disease: A Comparative Cross-Sectional Study. Sousa M; Moreira F; Jesus-Ribeiro J; Marques I; Cunha F; Canário N; Freire A; Januário C Eur Neurol; 2018; 79(1-2):13-20. PubMed ID: 29131091 [TBL] [Abstract][Full Text] [Related]
37. Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of anxiety symptoms in major depressive disorder: a meta-analysis of individual patient data from 10 double-blind, randomized clinical trials. Papakostas GI; Trivedi MH; Alpert JE; Seifert CA; Krishen A; Goodale EP; Tucker VL J Psychiatr Res; 2008 Jan; 42(2):134-40. PubMed ID: 17631898 [TBL] [Abstract][Full Text] [Related]
38. Interventional Study to Evaluate the Clinical Effects and Safety of the Nutraceutical Compound BrainUp-10® in a Cohort of Patients with Alzheimer's Disease: A Multicenter, Randomized, Double-Blind, and Placebo-Controlled Trial. Guzman-Martinez L; Farías GA; Tapia JP; Sánchez MP; Fuentes P; Gloger S; Maccioni RB J Alzheimers Dis; 2021; 81(3):1231-1241. PubMed ID: 33935080 [TBL] [Abstract][Full Text] [Related]
39. Safety and Exploratory Efficacy at 36 Months in Open-HART, an Open-Label Extension Study of Pridopidine in Huntington's Disease. McGarry A; Kieburtz K; Abler V; Grachev ID; Gandhi S; Auinger P; Papapetropoulos S; Hayden M J Huntingtons Dis; 2017; 6(3):189-199. PubMed ID: 28826192 [TBL] [Abstract][Full Text] [Related]
40. Bupropion for control of hot flashes in breast cancer survivors: a prospective, double-blind, randomized, crossover, pilot phase II trial. Nuñez GR; Pinczowski H; Zanellato R; Tateyama L; Schindler F; Fonseca F; Del Giglio A J Pain Symptom Manage; 2013 Jun; 45(6):969-79. PubMed ID: 23017618 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]